Unknown

Dataset Information

Experience with fingolimod in clinical practice.


ABSTRACT:

Aim

To report experience with fingolimod in clinical practice.

Design/methods

Patients in an academic medical center who were prescribed fingolimod from October 2010 to August 2011 were identified through the electronic medical record and followed for 12 months after fingolimod initiation. Adverse effects (AEs), clinical measures, MRI data, and quality of life measures were assessed.

Results

Three hundred seventeen patients started fingolimod. Eleven patients were treatment naïve (3.5%) and 76 (24.0%) had remote disease modifying therapy (DMT) use prior to fingolimod. One hundred fifty-one (47.6%) switched because of patient preference and 79 (24.9%) switched because of breakthrough disease. About 11.6% transitioned from natalizumab. Follow-up data were available for

SUBMITTER: Hersh CM 

PROVIDER: S-EPMC4414718 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature